PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade.
Authors: Ganbaatar Otgontuya, Konnai Satoru, Okagawa Tomohiro, Nojima Yutaro, Maekawa Naoya, Minato Erina, Kobayashi Atsushi, Ando Ryo, Sasaki Nobuya, Miyakoshi Daisuke, Ichii Osamu, Kato Yukinari, Suzuki Yasuhiko, Murata Shiro, Ohashi Kazuhiko
Journal: PloS one
Summary
# Editorial Summary: PD-L1 Expression in Equine Malignant Melanoma Equine malignant melanoma represents a significant clinical challenge, yet the immunological mechanisms underlying tumour progression remain poorly understood in horses. This research identified and characterised the equine PD-1/PD-L1 pathway—an immune checkpoint system known to suppress T-cell function in other species—and investigated whether blocking this pathway could restore immune responses against melanoma. Using molecular sequencing, flow cytometry, and immunohistochemistry, the team confirmed that PD-L1 is expressed in equine melanoma tissue and demonstrated that cross-reactive anti-bovine PD-L1 monoclonal antibodies successfully bound equine PD-L1 and blocked the inhibitory interaction between PD-1 and PD-L1. Crucially, blocking this checkpoint in cultured equine immune cells enhanced production of Th1 cytokines—the inflammatory responses typically needed to combat tumours—suggesting that checkpoint inhibition could restore anti-tumour immunity. These findings open a therapeutic avenue previously unexplored in equine oncology; whilst further work is needed to establish clinical efficacy and optimal dosing protocols, this research provides the immunological foundation for developing immunotherapy approaches that could potentially improve outcomes in horses with malignant melanoma, a condition for which current treatment options remain limited.
Read the full abstract on PubMed
Practical Takeaways
- •PD-L1 checkpoint inhibition may represent a novel immunotherapy avenue for equine melanoma, though clinical efficacy remains to be determined
- •Existing anti-bovine PD-L1 antibodies can be used as research tools for studying equine immune pathways, but equine-specific therapeutics will be needed for clinical application
- •Further investigation is needed before any immunotherapy protocols can be recommended for clinical use in horses with melanoma
Key Findings
- •Anti-bovine PD-L1 monoclonal antibodies successfully cross-react with equine PD-L1 and block PD-1/PD-L1 binding
- •PD-L1 expression was confirmed in equine malignant melanoma tumor tissues by immunohistochemistry
- •PD-L1 blockade enhanced Th1 cytokine production in equine immune cells in vitro
- •Equine PD-1 and PD-L1 amino acid sequences share considerable identity with non-primate species homologs